Carisma Therapeutics announces $53 million Series A financing

27. June 2018

|In Portfolio News

|By eazee-designstudio

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focused on the development of macrophage-based immunotherapeutics, today announced the close of a $53 million Series A financing to further expand its CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages – and to rapidly drive its programs toward clinical development.